Object | Object Dosea | Precipitant | Precipitant Therapeutic Class | Precipitant Dosea | % Change in AUCb | Reference |
---|---|---|---|---|---|---|
Sulfasalazine | 2-g SD | Curcumin | Food products | 2-g SD | 220 | Kusuhara et al., 2012 |
500-mg SD | Pantoprazole | Proton pump inhibitors | 40-mg SD | 83c | Adkison et al., 2010 | |
100-μg SD | Curcumin | Food products | 2-g SD | 83 | Kusuhara et al., 2012 | |
Rosuvastatin | 10 mg QD × 10 days | Cyclosporine | Immunosuppressants | 75 to 200 mg BID (stable dose for at least 2 mo) | 610d | Simonson et al., 2004 |
10-mg SD | Atazanavir + ritonavir | Protease inhibitors | 300 mg atazanavir + 100 mg ritonavir QD × 6 days | 210 | Busti et al., 2008 | |
20 mg QD × 7 days | Lopinavir + ritonavir | Protease inhibitors | 400 mg lopinavir + 100 mg ritonavir BID × 7 days | 110 | Kiser et al., 2008 | |
10-mg SD | Eltrombopag | Platelet-stimulating agents | 75 mg QD × 5 days | 55 | Allred et al., 2011 | |
10-mg SD | Elvitegravir + cobicistat | AIDS treatments | 150 mg elvitegravir + 150 mg cobicistat QD × 10 days | 40 | Custodio et al., 2014 | |
10-mg SD | Tipranavir + ritonavir | Protease inhibitors | 500 mg tipranavir + 200 mg ritonavir BID × 11 days | 37 | Pham et al., 2009 |
BID, twice daily; QD, once daily; SD, single dose.
↵a The route of administration was oral in all cases.
↵b Values were extracted from the Drug Interaction Database and calculated as the change in mean AUC values.
↵c AUC change observed with 421A/C genotype and was not statistically different from control.
↵d Change in AUC was calculated using healthy historical controls.